Franck Zal France

Hemarina Hemarina : A breakthrough in oxygen carriers for human health. Industry sectors Biotech Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Gastroenterology / Hepatology
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Pulmonary/Respiratory Diseases
Rare Disease
Your innovative solution

Hemarina develops products that constitute a decisive technological breakthrough in regard to current or past developments of hemoglobin-based oxygen carriers (HBOCs).

Which problem are you solving ?

HEMOXYcarrier´┐Ż = Universal oxygen carrier (Lack of blood worldwide is ~ 100 millions liters per year) - HEMO2Life : Organ & Tissue preservation - HEMHealing : Wound Healing & Repair

Target market segments

1/ Blood Oxygen Transporter, 2/ Organ & Tissue preservation, 3/ /Wound Healing & Repair

Key value proposition

1/ Unique know how from development to production of oxygen carriers 2/ Strong academic network & partnerships 3/ Broad intellectual property covering Hemarina's technology 4/ international publications

Hemarina SA
CEO 

Prof. Zyed ZALILA France

Intellitech Robust Predictive Modeling of Complex Processes based on an Intelligent Analysis of Big / Smart Data Industry sectors Other: Predictive Me Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology
Your innovative solution

Our xtractis' robot incorporates the latest advances in Artificial Intelligence, especially Fuzzy Logic and Machine Learning. It analyses a multidimensional database and automatically discovers robust fuzzy rule-based Decision Support Systems which are able to predict with the most reliability the complex process under study.

Which problem are you solving ?

Robust Predictive Models for Epigenetics Personalized Medicine and Pharmacogenomics: Drug Discovery (efficiency, toxicity), Early Diagnosis, Companion Diagnostic, Virtual Screening, Selection of Best Target Patients, Disease Evolution, Survival Duration, Preventive Care, Environmental/Life-style/Diet/Therapeutic Recommendations, Side Effects & Adverse Events, Protein Homology, Reimbursement Rate of a Drug, Insurance Risk Scoring of a Patient

Target market segments

Pharmaceutical Industry / Personalized Medicine Diagnostics / Hospitals & Medical Centers / Private or Public Insurers

Key value proposition

Unique mathematical approach (fuzzy, possibilistic, inductive, automatic, holistic, non-linear, non-monotonic, without a priori) / Proprietary algorithms implemented in fully automated software with user-friendly MMI / Better predictive capacity (robustness) vs. prevailing world-class techniques / Handles weak signals and low quality data

Website:
www.xtractis.com
Intellitech
President and CEO 

Mr Gary Zammit United States

If you’ve been looking for something different from your CRO, choose the one that stands out.

Welcome to Clinilabs, where science leads business.

Clinilabs is a premier full-service CRO that specializes in applying scientific principles to phase I, II, and III studies in order to bring investigational products to the threshold of successful approval.  Our unique development strategy builds value into early phase development programs, carrying promising products forward swiftly and abandoning failures early.  We enable our clients to apply their resources wisely and maximize the value of their drug and device portfolios.
 
Expect something different from your CRO – Science. Communication. Collaboration. Results. 

Clinilabs
President & CEO 

Miss Zoe ZHANG Canada

Coolaborator
BD Director 

Stephen Harvey . Zinner, M.D United States

Mount Auburn Hospital was founded in 1886 as the first hospital in Cambridge, Massachusetts. Over the years, generations of committed individuals have dedicated their careers to achieving the vision of being the best community teaching healthcare system in the Boston area. On a mission to improve the health of the residents of Cambridge and surrounding communities, Mount Auburn Hospital is dedicated to delivering healthcare services in a personable, convenient, and compassionate manner, with respect for the dignity of patients and their families.

Mount Auburn Hospital is affiliated with Harvard Medical School, making significant contributions to educating the caregivers of tomorrow.  The hospital is fully accredited by the Joint Commission on Accreditation of Healthcare Organizations and is a member of the American Hospital Association, the Council of Teaching Hospitals, and the Association of American Medical Colleges.

Mount Auburn provides a number of clinical services to Cambridge and surrounding communities, including cardiac catheterization, laboratory services, rehabilitation services, and specialized services for men, women and seniors.

Mount Auburn Hospital - Havard Medical School
Professor of Medicine - Department of Medicine 

Dr Bhagwagar Zubin United States

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

Alexion developed Soliris® (eculizumab) from the laboratory through commercialization for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening, ultra-rare disorders. Today, Soliris is approved in nearly 50 countries for PNH and nearly 40 countries for aHUS. Download Soliris prescribing information.

As we continue to expand our operations into additional countries, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. Alexion is establishing a premier global metabolic rare disease franchise with two potential therapies in late-stage development, Strensiq™ (asfotase alfa) for hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL Deficiency, or LAL-D). Strensiq has been approved in the EU and Japan for the treatment of patients with HPP, and Kanuma has been approved in the EU for the treatment of patients with LAL-D. In addition, as the global leader in complement inhibition, we are strengthening and broadening our portfolio of complement inhibitors across diverse platforms, including evaluating potential indications for Soliris in additional severe and ultra-rare disorders.

Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012.

Our global headquarters and research operations are in Cheshire, Conn., and will move to New Haven, Conn. in 2015. Alexion's more than 2,800 employees serve patients in 50 countries.

Website:
http://alxn.com/
Alexion
Executive Director